Vibeke Berg Logager

Dr. Vibeke Berg Logager

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2012 in European Radiology
Verified
Journal Article
Open access
PDF file
JBJelle O. Barentsz
Jelle O. Barentsz
JRJonathan Richenberg
Jonathan Richenberg
RCRichard Clements
Richard Clements
PCPeter Choyke
Peter Choyke
SVSadhna Verma
Sadhna Verma
JFJurgen J. Fütterer
Jurgen J. Fütterer
The aim was to develop clinical guidelines for multi-parametric MRI of the prostate by a group of prostate MRI experts from the European Society of Urogenital Radiology (ESUR), based on literature evidence and consensus expert opinion. True evidence-based guidelines could not be formulated, but a compromise, reflected by “minimal” and “optimal” requirements has been made. The scope of these ESUR guidelines is to promulgate high quality MRI in acquisition and evaluation with the correct indications for prostate cancer across the whole of Europe and eventually outside Europe. The guidelines for the optimal technique and three protocols for “detection”, “staging” and “node and bone” are presented. The use of endorectal coil vs. pelvic phased array coil and 1.5 vs. 3 T is discussed. Clinical indications and a PI-RADS classification for structured reporting are presented. Key Points • This report provides guidelines for magnetic resonance imaging (MRI) in prostate cancer. • Clinical indications, and minimal and optimal imaging acquisition protocols are provided. • A structured reporting system (PI-RADS) is described.

19 November 2014 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
LBLars Boesen
Lars Boesen
ECElizaveta Chabanova
Elizaveta Chabanova
VLVibeke Berg Logager
Vibeke Berg Logager
IBIngegerd Balslev
Ingegerd Balslev
HTHenrik S. Thomsen
Henrik S. Thomsen

1 January 2007 in Cancer Imaging
Verified
Journal Article
Open access
HTHenrik S Thomsen
Henrik S Thomsen
PMPeter Marckmann
Peter Marckmann
VLVibeke Berg Logager
Vibeke Berg Logager
Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents - Cancer Imaging Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents - Until recently it was believed that extracellular gadolinium based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium based contrast agents may trigger the development of nephrogenic systemic fibrosis, a generalised fibrotic disorder, in renal failure patients. Accordingly, the use of gadodiamide and gadopentate dimeglumine for renal failure patients was banned in Europe in spring 2007.

11 December 2014 in European Radiology
Verified
Journal Article
Closed access
PDF file
LBLars Boesen
Lars Boesen
ECElizaveta Chabanova
Elizaveta Chabanova
VLVibeke Berg Logager
Vibeke Berg Logager
IBIngegerd Balslev
Ingegerd Balslev
KMKari Mikines
Kari Mikines
HTHenrik S. Thomsen
Henrik S. Thomsen

1 November 2008 in Magnetic Resonance Imaging Clinics of North America
Verified
Journal Article
Closed access
HTHenrik S. Thomsen
Henrik S. Thomsen
PMPeter Marckmann
Peter Marckmann
VLVibeke Berg Logager
Vibeke Berg Logager

17 August 2016 in Acta Radiologica Open
Verified
Journal Article
Open access
KTKaren Cecilie Duus Thestrup
Karen Cecilie Duus Thestrup
VLVibeke Berg Logager
Vibeke Berg Logager
IBIngerd Baslev
Ingerd Baslev
JMJakob M Møller
Jakob M Møller
RHRasmus Hvass Hansen
Rasmus Hvass Hansen
HTHenrik S Thomsen
Henrik S Thomsen
Background: Since multiparametric magnetic resonance imaging (mp-MRI) of the prostate exceeds 30 min, minimizing the evaluation time of significant (Gleason scores > 6) prostate cancer (PCa) would be beneficial. A reduced protocol might be sufficient for the diagnosis. Purpose: To study whether a short unenhanced biparametric MRI (bp-MRI) matches mp-MRI in detecting significant PCa. Material and Methods: A total of 204 men (median age, 65 years; mean ± SD, 64.1; range 45–75 years; median serum PSA level, 14 ng/mL; range, 2.2–120 ng/mL; median prostate volume, 60 mL; range, 23–263 mL) fulfilled the criteria for being enrolled. They underwent mp-MRI and prostate biopsy from January through June 2014. Of the included patients, 9.3% underwent prostatectomy, 90.7% had TRUS-bx, and 10.8 had MRI-targeted TRUS-bx. Two radiologists separately assessed the mp-MRI examination (T2-weighted [T2W] imaging, diffusion-weighted imaging [DWI], apparent diffusion coefficient map [ADC-map] and dynamic contrast-enhanced imaging [DCE]). Two months later, the bp-MRI version (T2W imaging, DWI, and ADC-map) was evaluated. Results: Reader 1: Assessing mp-MRI: 0 false negatives, sensitivity of 1, and specificity 0.04. Assessing bp-MRI: four false negatives, sensitivity of 0.94, and specificity 0.15. Reader 2: Assessing mp-MRI: five false negatives, sensitivity of 0.93, and specificity 0.16. Assessing bp-MRI: three false negatives, sensitivity of 0.96, and specificity 0.15. Intra-reader agreement Cohen’s Kappa (κ) was 0.87 for reader 1 (95% confidence interval [CI], 0.83–0.92) and 0.84 for reader 2 (95% CI 0.78–0.89). Conclusion: Bp-MRI is as good as mp-MRI at detecting PCa. A large prospective study seems to be strongly warranted.